Search results for: ruconest

From the Pharming Group N.V. financial report for the first quarter ended 31 March 2016: During the quarter we initiated sales of Ruconest in the countries which Pharming now commercializes directly, in Germany, Austria and the Netherlands . These countries had proved very difficult for our partner SOBI prior to 2015 when we agreed to take [...]

In the financial report for the full year that ended 31 December 2015 Sijmen de Vries, CEO and Chairman of the Board of Pharming Group N.V. writes (in extracts): 2015 was the year that Pharming started to move forward again, after years of consolidation and transition. Sales of Ruconest grew well in 2015. This was most strongly seen in [...]

Pharming Group N.V. reiterates it commitment to the treatment of rare diseases on Rare Disease Day 2016, an annual global initiative committed to improving public understanding of rare diseases and highlighting the exceptional challenges facing patients and their carers. Nearly 7,000 different rare diseases have been identified to date, directly affecting the daily life of [...]

Following evaluation of a dossier submitted by Pharming Group N.V. last year, the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion to the European Commission on the company's request to include the treatment of HAE attacks in adolescents with HAE and to remove the requirements for rabbit IgE testing that forms part [...]

  Biotech company Pharming Group N.V. has published its (unaudited) financial report for the six months ended 30 June 2015. From the operational highlights: Following the completed acquisition of our US partner, Salix Pharmaceuticals by Valeant Pharmaceuticals (VRX), the Ruconest US commercial infrastructure remains intact and commercialisation continues to be unaffected. A steady inflow of new [...]

The global collaboration between Clinigen Group plc and Pharming Group N.V. to provide access to Pharming’s Ruconest (conestat alfa) is now live. The unique access program was initiated by HAEi, the International Patient Organization for C1- Inhibitor Deficiencies. Ruconest is a recombinant human C1- inhibitor, approved by the European Medicines Agency (EMA) and US Food [...]

Pharming Group N.V. and Clinigen Group plc have entered into an international global access collaboration for HAEi. The “HAEi GAP” program will provide access to RUCONEST® (conestat alfa) to eligible patients with HAE, who currently do not have access to effective medication to treat acute attacks of the disease. HAEi GAP is the first global [...]

Landmark global program opens access to HAE medicine to rare disease sufferers for the first time Lausanne, Switzerland – 16 May 2015 – Thousands of patients suffering from a rare and potentially fatal genetic disease will have access to medicines for the first time, with the launch of the HAEi Global Access Program (HAEi [...]

Pharming Group N.V. has published its (unaudited) financial report for Q1 2015 ended 31 March 2015. From the financial highlights: Ruconest sales in the US amounted to 0.6 million EUR and sales by Sobi in the EU amounted to 0.4 million EUR. Alongside Pharming realised initial direct sales in Austria, Germany and the Netherlands. Product [...]

Pharming Group N.V. has nominated Paul Jai Sekhri and Jan Hendrik Egberts as members of the Board of Supervisory Directors. The nominations will be subject to shareholders’ approval at the upcoming Annual General Meeting of Shareholders, which will take place on 30 April 2015. Mr. Sekhri (1958) has over 28 years of operational experience in [...]

Pharming Group N.V. has published its preliminary (unaudited) financial results for the year ended 31 December 2014. From the financial highlights: Revenues from operations increased to 21.2 million EUR (2013: 6.8 million EUR) as a result of higher license fees, including the receipt of a 20.0 million USD (16 million EUR) milestone from US partner [...]